Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis

Tumor tissues are often absent or insufficient for testing epidermal growth factor receptor (EGFR) mutations to guide EGFR tyrosine kinase inhibitors (TKIs) treatment of patients with nonsmall cell lung cancer (NSCLC). We conducted this systematic review and meta-analysis to assess whether blood can...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Chen, Yuan, Jin-Qiu, Yang, Zu-Yao, Fu, Xiao-Hong, Wu, Xin-Yin, Tang, Jin-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616411/
https://www.ncbi.nlm.nih.gov/pubmed/26020382
http://dx.doi.org/10.1097/MD.0000000000000775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616411/
https://www.ncbi.nlm.nih.gov/pubmed/26020382
http://dx.doi.org/10.1097/MD.0000000000000775

Ejemplares similares